MA-LG-CHEM
22.2.2021 23:35:11 CET | Business Wire | Press release
LG Chem Life Sciences (“LG Chem”) today announced the first healthy adult volunteer has been safely dosed in the phase I study of LG00303174 being run in the US.
LG Chem licensed LG00303174 (TT-01025) from TransThera Biosciences Co. Ltd. (“TransThera”), a clinical-stage biotechnology company based in Nanjing, China. LG Chem had entered into an exclusive license agreement with TransThera in August 2020 to research, develop, manufacture, and commercialize LG00303174 in the world except China and Japan.
LG00303174 is a potential best-in-class novel SSAO/VAP-1 inhibitor, currently being developed for the treatment of chronic inflammatory diseases, including non-alcoholic steatohepatitis (NASH). The phase 1 study is currently being conducted within the U.S. and approximately 64 subjects are expected to be enrolled.
“The commencement of this study is a significant landmark for LG Chem as we are determined to address the clear unmet needs of those with metabolic disease,” said Adam Benson, Director of Clinical Development of LG Chem Life Sciences Innovation Center in Cambridge, MA. “NASH to this day remains an elusive target. We feel strongly that LG00303174 has shown, in pre-clinical models, to have a strong safety profile, and as an oral therapy, has the potential to address a clear need in a disease that is becoming increasingly burdensome to our healthcare system.”
Dr. Frank Wu, CEO of TransThera, commented: “We congratulate LG Chem team on the rapid implementation of FIH trial in the United States, which marks a key milestone for this collaboration program.”
According to Dr. Jeewoong Son, President of LG Chem Life Sciences in Seoul, Korea, the fast and efficient implementation of this phase 1 study “is a testament to our clinical development capabilities of the LG Chem Life Sciences Innovation Center in Cambridge as a center of excellence to enrich and forward our development pipeline.”
About LG Chem Life Sciences
LG Chem Life Sciences is a business division within LG Chem, engaged in the development, manufacturing, as well as commercializing pharmaceutical products globally. LG Chem Life Sciences seeks to expand and make global presence by focusing on key core therapeutic areas of Immunology, Oncology, and Metabolic Diseases (specifically, diabetes and related metabolic diseases). To achieve such, its strategy is to actively pursue global collaboration encompassing from asset-centric to strategic investment and collaboration.
LG Chem Life Sciences Innovation Center: innovation.lgchem.com
About TransThera Biosciences
TransThera Biosciences is a clinical-stage biotechnology company dedicated to developing innovative therapeutics to target diseases with major unmet medical needs via internal research platform and open innovation. TransThera's current portfolio covers therapeutic areas such as oncology, cardiovascular, and inflammatory diseases. For more information, please visit www.transtherabio.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005934/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Paymentology Raises $175 Million co-led by Apis Partners and Aspirity Partners to Support Next Phase of Growth12.5.2026 09:01:00 CEST | Press release
Paymentology, the leading global issuer-processor, today announced a $175 million investment co-led by Apis Partners (”Apis”), a private equity firm specialising in financial infrastructure and services, and Aspirity Partners (“Aspirity”), a pan-European Private Equity firm focused on Financial Technology & Services and Enterprise Technology & Connectivity Services. The investment will support Paymentology’s continued global expansion, product development and strengthening of its team, as the company builds on strong demand for modern issuer processing on a global scale. The transaction brings together two investors with deep experience in the payments industry and a shared focus on advancing payments infrastructure, united by the view that issuer processing represents one of the most significant opportunities in the sector. For Apis, the investment, made by Apis Growth Fund III1, marks the firm’s 16th payments investment. Both Apis and Aspirity will draw on their deep sector and globa
IQM Launches HPC Integration Service to Accelerate Hybrid Quantum-HPC Adoption12.5.2026 09:00:00 CEST | Press release
IQM Radiance systems now operate as computational nodes inside HPC environments. The hybrid workflows are scheduled and managed alongside CPUs and GPUs by the same workload manager already operational in the world’s top supercomputing centers. The new HPC Integration Service reflects the company’s production quantum model – end-users own the hardware, run it on their infrastructure, and operate it under their control. IQM Quantum Computers today launched HPC Integration Service, a turnkey solution that enables its IQM Radiance quantum computers to operate as a slurm node inside high-performance computing (HPC) environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512187465/en/ IQM Radiance quantum computer (right) co-located with classical HPC infrastructure (left) in a data center environment. Using this widely adopted HPC workflow, IQM aims at accelerating adoption of hybrid quantum-classical computing across ente
Visa Flexible Credential Brings More Flexible Ways to Pay to Zilch Cardholders in the UK12.5.2026 09:00:00 CEST | Press release
Visa, Zilch and Thredd collaborate to help issuers deliver a simpler, more flexible card experience for users. Visa, a world leader in digital payments, Zilch and Thredd today announced the introduction of Visa Flexible Credential (VFC) on Zilch cards in the UK, enabling more flexible ways to pay through a single, familiar card experience. Demand for flexible payment experiences continues to grow. Many people no longer think in fixed terms such as debit or credit, instead wanting the ability to choose what works best for a specific purchase in the moment. In the UK, 87% of people surveyed say flexible payment options support their financial or lifestyle goals1. Visa Flexible Credential is designed to support this shift, helping issuers offer more choice through one familiar card that already works at more than 150 million merchant locations worldwide. The new capability allows different payment options to sit behind one card or digital credential, giving cardholders greater choice and
AMP IT Announces New Funding Round to Scale Its Private EV Charging as a Service in Switzerland and Beyond12.5.2026 08:43:00 CEST | Press release
AMP IT, a Geneva-based energy and mobility company, today announced the successful completion of a new funding round to accelerate the deployment of its private EV charging and energy management platform across Switzerland and international markets. Founded in 2021, AMP IT develops, finances, installs, and operates smart EV charging infrastructure for residential buildings, commercial real estate, and corporate fleets. Through its charging-as-a-service model, the company combines infrastructure with its proprietary software, AMP IT Hub, delivering a fully integrated energy solution. The latest funding round, supported notably by the Swiss Technology Fund, brings AMP IT’s total funding to €7 million since inception. The capital will support operational scaling, further development of its software platform, and expansion into selected European markets. “Users are increasingly looking for solutions that are simple, efficient, and affordable which is exactly what we provide,” said Florian
New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden12.5.2026 08:30:00 CEST | Press release
− Reductions in All-Cause Mortality and Recurrent Cardiovascular Events Maintained Across Key Patient Subgroups, Including Patients Taking a Broad Range of Heart Failure Therapies –− Pooled Analysis of Over 25,000 Patient-Years of Experience with TTR-Silencing RNAi Therapies Shows a Consistent Safety Profile, Including No Clinically Meaningful Ocular Effects of Vitamin A Lowering –− DemonsTTRate Study Designed to Generate Long-Term Real-World Evidence in More Than 2,000 Patients with ATTR-CM − Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new analyses from the HELIOS-B Phase 3 study of vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), adding to the growing body of evidence supporting vutrisiran and reinforcing the durability of transthyretin (TTR) knockdown and its well-characterized safety profile. Vutrisiran is the first and only TTR silencer approved for ATTR-
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom